USNA

USANA Health Sciences, Inc. (USNA) Business Model Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Demand Quality

Revenue base remains supported by a low valuation multiple, with price-to-sales at 0.27x and enterprise value to sales at 0.09x.

Demand quality appears mixed, as gross margin remains strong at 77.4% but operating margin is only 1.35% and net margin is -2.43%.

Profitability Cash Generation

Cash generation is still positive, with free cash flow yield at 6.45% and free cash flow to operating cash flow at 57.5%.

Earnings quality remains weak, with return on equity at -4.16%, return on invested capital at -23.8%, and income quality still negative at -0.97.

Balance Sheet Capital Efficiency

The balance sheet remains conservative, with no debt and a current ratio of 2.66x.

Liquidity is strong, with cash ratio at 1.60x and net current asset value of $148.8M, while capital intensity stays modest with capex at 1.29% of revenue.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on USANA Health Sciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →